Medpace Holdings, Inc. $MEDP Stock Holdings Trimmed by Cabot Wealth Management Inc.

Cabot Wealth Management Inc. lessened its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.9% in the second quarter, according to its most recent filing with the SEC. The firm owned 26,548 shares of the company’s stock after selling 1,077 shares during the quarter. Medpace comprises approximately 1.4% of Cabot Wealth Management Inc.’s holdings, making the stock its 24th largest position. Cabot Wealth Management Inc.’s holdings in Medpace were worth $14,060,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. BOKF NA lifted its stake in Medpace by 0.8% in the third quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after buying an additional 20 shares in the last quarter. Valeo Financial Advisors LLC increased its position in shares of Medpace by 5.0% during the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after acquiring an additional 21 shares in the last quarter. UMB Bank n.a. raised its holdings in shares of Medpace by 5.6% during the fourth quarter. UMB Bank n.a. now owns 450 shares of the company’s stock worth $253,000 after acquiring an additional 24 shares during the period. Schulhoff & Co. Inc. raised its holdings in shares of Medpace by 1.1% during the fourth quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock worth $1,237,000 after acquiring an additional 25 shares during the period. Finally, Balefire LLC lifted its position in Medpace by 6.1% in the 1st quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after acquiring an additional 26 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Insider Buying and Selling

In other Medpace news, CEO August J. Troendle sold 458 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $600.39, for a total transaction of $274,978.62. Following the sale, the chief executive officer directly owned 603,978 shares of the company’s stock, valued at approximately $362,622,351.42. This represents a 0.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Cornelius P. Mccarthy III sold 1,140 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total transaction of $690,121.80. Following the completion of the sale, the director owned 12,275 shares of the company’s stock, valued at approximately $7,430,916.75. This represents a 8.50% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 67,195 shares of company stock worth $37,989,998. 20.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

MEDP has been the subject of a number of research analyst reports. Leerink Partners set a $620.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Truist Financial lifted their price target on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Robert W. Baird boosted their price target on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. BMO Capital Markets upped their price objective on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. Finally, Mizuho increased their price objective on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $584.18.

Medpace Stock Performance

NASDAQ:MEDP opened at $578.50 on Friday. The stock’s 50-day simple moving average is $536.23 and its 200 day simple moving average is $492.35. The company has a market cap of $16.15 billion, a P/E ratio of 33.91, a P/E/G ratio of 2.60 and a beta of 1.15. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.